米诺环素对氟尿嘧啶诱导的小鼠肠黏膜炎的保护作用研究

Abstract
Figure/Table
References (20)
Related Citation (1)

Download: PDF (566 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective Forty investigate the protective effect of Minocycline on 5-Fu induced intestinal mucostitis. Methods 40 male Balb/c mice were randomly divided into four groups (n = 10), Control group, 5-Fu induced mucositis model, high dose or low dose of Minocycline treated group. After the mice were intraperitoneal administrated with 80 mg/kg 5-Fu for 3 days and simultaneously treated with 30 or 60 mg/kg orally in Balb/c mice, the body weight loss, diarrhea scores, and HE stain of the intestinal, pro-inflammatory cytokines in intestine tissue and short chain fatty acids in colon contents were also determined. Results Data from this study indicated that high dose minocycline could attenuate the 5-Fu induced body weight loss (P < 0.01), and lower the diarrhea scores (P < 0.01). Also minicycline in high dose increased the intestinal vill length (P < 0.01), decreased the IL-6 (P < 0.05) and TNF-α (P < 0.01). In the colon contents, Minocycline could significantly increase the SCFAs concentration, especially for aceticacid butyricacid (P < 0.01). Conclusion All these results demonstrated that Minocycline exert protective effects on 5-Fu induced intestinal damage in mice, and these protective effects may partially oriented from its anti-inflammatory effects and enhancing short chain fatty acid production.

Key words： Minocycline 5-Fluorouracil Intestinal mucositis Short-chain fatty acid

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Yixin LIU Wei

Cite this article:

HUANG Yixin LIU Wei. Protective effects of Minocycline on 5-Fluorouracil-induced intestinal mucositis in mice[J]. 中国医药导报, 2019, 16(10): 20-24.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I10/20

[1] Kengkla K，Kongpakwattana K，Saokaew S，et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections：a systematic review and network meta-analysis [J]. J Antimicrob Chemother，2018，73（1）：22-32.
[2] Garrido-Mesa N，Zarzuelo A，Gálvez J. Minocycline: far beyond an antibiotic [J]. Br J Pharmacol，2013，169（2）：337-352.
[3] Livermore DM，Mushtaq S，Warner M，et al. In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii [J]. Antimicrob Agents Chemother，2016，60（6）：3840-3844.
[4] Bahrami Z，Firouzi M，Hashemi-Monfared A，et al. The effect of minocycline on indolamine 2，3 dioxygenase expression and the levels of kynurenic acid and quinolinic acid in LPS-activated primary rat microglia [J]. Cytokine，2018，107：125-129.
[5] Bonjoch L，Gea-Sorlí S，Jordan J，et al. Minocycline inhibits peritoneal macrophages but activates alveolar mac-rophages in acute pancreatitis [J]. J Physiol Biochem，2015，71（4）：839-846.
[6] Aketa H，Tatsumi T，Kohga K，et al. The combination therapy of α-galactosylceramide and 5-fluorouracil showed antitumor effect synergistically against liver tumor in mice [J]. Int J Cancer，2013，133（5）：1126-1134.
[7] Cheng M，Liu Z，Wan T，et al. Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice [J]. Cancer Biol Ther，2012，13（14）：1407-1416.
[8] Tang M，Lu X，Zhang C，et al. Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer [J]. Theranostics，2017，7（5）：1346-1359.
[9] Spencer NJ. Motility patterns in mouse colon：gastrointestinal dysfunction induced by anticancer chemotherapy [J]. Neurogastroenterol Motil，2016，28（12）：1759-1764.
[10] Chang CT，Ho TY，Lin H，et al. 5-Fluorouracil induced intestinal mucositis via nuclear factor-kappa B activation by transcriptomic analysis and in vivo bioluminescence imaging [J]. PLoS One，2012，7（3）：e31808.
[11] Zhang S，Liu Y，Xiang D，et al. Assessment of dose-response relationship of 5-fluorouracil to murine intestinal injury [J]. Biomed Pharmacother，2018，106：910-916.
[12] Ohkusa T，Yoshida T，Sato N，et al. Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion：a possible pathogenic mechanism of ulcerative colitis [J]. J Med Microbiol，2009，58：535-545.
[13] Shimamura Y，Takeuchi I，Terada H，et al. A mouse model for oral mucositis induced by cancer chemotherapy [J]. Anticancer Res，2018，38（1）：307-312.
[14] Pinto A，Fidalgo P，Cravo M，et al. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: randomized，double-blind，controlled trial [J]. Dis Colon Rectum，1999，42（6）：788-795，795-796.
[15] Ooi C，Good N，Williams D，et al. Efficacy of butyrate analogues in HT-29 cancer cells [J]. Clin Exp Pharmacol Physiol，2010，37（4）：482-489.
[16] 傅红，师英强，莫善兢.短链脂肪酸对人结肠癌Caco-2细胞增殖分化的影响与临床意义[J].中华消化杂志，2003，23（8）：473-475.
[17] Saif MW，Diasio RB. Benefit of uridine triacetate （Vistogard） in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase （DPYD） deficiency [J]. Cancer Chemother Pharmacol，2016，78（1）：151-156.
[18] Yuan L，Zhang S，Li H，et al. The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer [J]. Biomed Pharmacother，2018，108：184-193.
[19] Le Bastard Q，Ward T，Sidiropoulos D，et al. Fecal microbiota transplantation reverses antibiotic and chemotherapy-induced gut dysbiosis in mice [J]. Sci Rep，2018，8（1）：6219.
[20] Hamouda N，Sano T，Oikawa Y，et al. Apoptosis，dysbiosis and expression of inflammatory cytokines are sequential events in the development of 5-fluorouracil-induced intestinal mucositis in mice[J]. Basic Clin Pharmacol Toxicol，2017，121（3）：159-168.